Moreover, QTc duration in the active phase always remained significantly increased in COVID-19 patients with respect to controls, even in the absence of abnormal troponin/BNP levels or concomitant QT-prolonging risk factors (Supplementary Figure VI). The gene discussed is NPPB; the disease is COVID-19.